The importance of dose intensity has been strongly emphasized in high-risk breast cancer. Overexpression of erb B2 is clearly correlated with an overall poor prognosis which could be limited in patients receiving intensive chemotherapy with alkylating agents and autologous stem cell transplants (SST). Thirty-five patients with high-risk non-metastatic breast cancer (Ͼ4 involved lymph nodes), treated with high-dose chemotherapy (HDC) followed by SST were analyzed. All were previously treated by four cycles of standard-dose anthracycline or anthracene dione. Nine had erb B2 overexpression. Minimum follow-up duration was 41 months (median 68 months). At 5 years, the actuarial relapse-free survival is 57.4% and actuarial overall survival 67.4%. Patients with overexpression of erb B2 had significantly lower disease-free survivals (P: 0.021) and overall survivals (P: 0.001). On multivariate analysis, erb B2 overexpression appeared to be the single independent poor prognosis factor for relapse (RR 3.25, range 1.12 to 9.45) and overall (RR 5.28, range 1.74 to 16.03) survival. These results suggest that poor prognosis of erb B2 overexpression is unchanged after HDC with alkylating agents but a possible benefit may exist in these patients with the additional monoclonal antibody, herceptin. Bone Marrow Transplantation (2002) 29, 753-757.
after encouraging results reported in pilot studies, few adequate controlled studies have been reported to date to evaluate such benefit if it does exist. It is possible that only subgroups of patients, ideally better identified by biological features rather than clinical presentation, could benefit from such intensive strategies.
Currently, we and others are attempting to identify which prognostic factor, if any, may predict chemosensitivity to standard doses of chemotherapy. To date, biological parameters have failed to prove reliable predictivity. The p53, bcl2 status and mitotic index have been reported to be associated with sensitivity of the tumor to chemotherapy but the data available are somewhat contradictory in several studies. 1 Recently, more attention has been paid to the relevance of erb B2 overexpression to therapeutic response and to survival after therapy with conventional doses of chemotherapy for breast cancer. 2, 3 Erb B2, an oncogene which encodes a transmembrane glycoprotein of the epidermal growth factor receptor family, is overexpressed in 15-30% of breast cancers. 4 If such overexpression is frequently associated with shorter relapse-free and overall survivals its significance as an independent prognostic factor can vary between studies. Interestingly, it has been suggested that poor prognosis associated with erb B2 overexpression could be overcome in patients receiving high-dose chemotherapy, in the setting of standard chemotherapy: this observation was mainly made in patients treated with standard anthracycline therapies 5 and has not been validated in other studies. 6 Thus, it was tempting to establish whether poor prognosis associated with erb B2 overexpression could be abolished when patients were treated with high doses of alkylating agents and autologous stem cell transplant: in this situation dose intensity is maximal. We initiated this analysis in patients undergoing HDC with alkylating agents and autologous stem cell transplantation for poor risk breast cancer defined as more than four positive nodes. We sought to identify whether erb B2 overexpression was a prognosis factor for disease-free survival and overall survival.
Patients and methods
In this analysis, all patients who had received high-dose chemotherapy and hematopoietic stem cell transplantation for high risk non-metastatic non-inflammatory breast cancer were eligible. Inclusion criteria were as follows: у4 involved axillary lymph nodes; lack of distant metastasis; lack of contra-indication for high-dose chemotherapy; and age Ͻ60 years old.
Before HDC, all patients had surgery (radical mastectomy or tumorectomy with axillary lymph node dissection) and six courses of standard anthracycline or antracene dione-based chemotherapy. Twenty-five had doxorubicin- . 7 All had a bone marrow harvest yielding more than 2 ϫ 10 8 mononuclear cells/kg collected from bone marrow under general anesthesia (16 patients) according to a technique already described, 8 or peripheral blood harvest more than 2 ϫ 10 6 CD34 ϩ /kg collected by leukapheresis primed by a cycle of chemotherapy and subsequent subcutaneous recombinant granulocyte colony-stimulating factor (rG-CSF; Amgen, Thousand Oaks, CA, USA) (19 patients). After collection, cells were cryopreserved in dimethylsulfoxide.
High-dose chemotherapy and hematopoietic rescue
High-dose chemotherapy was administered as soon as possible after the last cycle of conventional chemotherapy, as already described. 9 Conditioning was a combination of mitoxantrone 12 mg/m 2 day from day Ϫ7 to day Ϫ5, cyclophosphamide 60 mg/kg/day from day Ϫ3 to day Ϫ2 and melphalan 140 mg/m 2 day Ϫ1. Stem cells were reinfused on day 0. Hematopoietic growth factor (rGCSF) was administered from day 0 until the absolute neutrophil count exceeded 0.5 ϫ 10 9 /l for 3 consecutive days following aplasia.
After hematological recovery, whole breast radiation was delivered using either cobalt 60 or 5-6 MeV photons to a median dose of 52 Gy. An additional boost was delivered to the tumor bed in cases of conservative surgery. Tamoxifen 20 mg/day was then administrated for 5 years if estrogen receptors were positive.
Histological analysis
All tumor specimens were reviewed by two pathologists. Breast cancers were classified according to the WHO recommendation. Older surgical samples were fixed in Bouin's fluid and more recent ones in alcohol formalin. Staining was performed on a Techmate 1000 automated immunohistochemistry stainer (Dako, Trappes, France). Erb B2 immunostaining was performed separately by two monoclonal antibodies as previously validated, 10 NeuAB3 for the external domain (Calbiochem, Meudon, France) and CB11 for internal domain (Novocastra/Tebu, Le Perray en Yvelines, France). Immunostaining was scored as positive for a plasma membrane labeling strong (ϩϩϩ) or weak (ϩϩ) and negative in the absence of plasma membrane positivity or only cytoplasmic labeling. In cases of discordance between the two antibodies only the strongest positivity was taken into account (however, no such cases were found in this short series). Hormonal receptors were determined on paraffin sections using immunohistochemistry techniques, 6F11 (Novocastra) for estrogen and PGR636 (Dako) for the progesterone receptor.
Statistical analysis
Breast cancer specific survival was calculated from the date of diagnosis, disease-related death being scored as an event, with censoring of other patients at the time of last followup. Disease-free interval was also calculated from the date of diagnosis, first distant or local recurrence being scored as an event with censoring of other patients at the time of last follow-up time.
Survival curves were estimated using the Kaplan-Meier method. 11 Curves were compared using the log rank test. Prognostic factors were assessed by multivariate analysis by the Cox proportional hazards model in a forward stepwise regression.
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Results
Patient characteristics
All 35 patients who had received high-dose chemotherapy with stem cell support between 1991 and 1995 were analyzed. Patient characteristics are summarized in Table 1 . The median number of involved lymph nodes was 12 (range 5-36). All had conventional chemotherapy (NCF: 10 patients or FAC: 25 patients) before high-dose chemotherapy and hematopoietic stem cell transplantation. Erb B2 overexpression was detected in nine of the 35 patients (25.7%). Estrogen receptors were positive for 71.9% and progesterone receptors for 68.8%. Figure 1 Disease-free survival in relation to erb B2. 
Overall survival and relapse
Median follow-up was 68 months (range 41-91 months). There were 11 metastatic relapses, three local relapses and 13 deaths. The actuarial event-free survival at 5 years was 57% and the median overall survival was 67.4%. There was a statistical difference between the erb B2-positive group and erb B2-negative one for overall ( Figure 1 ) and diseasefree survival (Figure 2) . At 5 years, disease-free survival was significantly shorter in patients with erb B2 overexpression (27.8%) than in patients with erb B2-negative tumor (72.1%) (P ϭ 0.02). Respectively, 5-year overall survival was 33.3% for patients with erb B2 overexpression and 79.2% for the other group (P ϭ 0.001).
On univariate analysis the estrogen receptor was the only other significant factor for overall survival (P ϭ 0.048), SBR grading, and tumor size were not significant, respectively, erb B2 was the only significant factor for event-free survival (Table 2) . On multivariate analysis erb B2 Table 3) .
Discussion
Increasing dose and dose intensity is currently a major concern in breast cancer chemotherapy. Despite encouraging results from pilot studies, randomized trials resulted in a major debate concerning high-dose chemotherapy and stem cell support. [13] [14] [15] [16] Finally, in optimizing chemotherapy for breast cancer there are still several pieces of information that are, as yet, unknown. For example, biological or clinical parameters appropriate for the selection of the subset of patients which could benefit from high-dose chemotherapy are still unknown. Number of involved lymph nodes is still the most reliable prognosis factor.
The dose-response effect of anthracycline has been reported in the Cancer Leukemia Group B trial 8541. Among these patients, Muss et al 5 demonstrated the impact of erb B2 overexpression as an independent prognostic factor as well as the benefits of high doses of anthracyclin in terms of overall and disease-free survival. Women with erb B2 overexpression receiving FAC 60 had a superior disease-free survival and overall survival rates when compared to women with erb B2 overexpression receiving lower doses of anthracycline. Thor et al 17 recently confirmed this significant correlation between erb B2 overexpression and response to high doses of anthracycline among 992 patients and a median follow-up of 10 years. Benefits of high-dose anthracycline (FAC 60 regimen) appeared to be confined to patients who over-expressed erb B2. 17 Conversely, there was no clear evidence of an effect of high-dose doxorubicin in patients with low or intermediate expression of erb B2; however, this trial lacks statistical power to detect small differences between doses of anthracycline in erb B2-negative tumors. This sensitivity of erb B2-positive tumors to higher doses of anthracycline supported our retrospective analysis of high-dose alkylating-based chemotherapy and stem cell rescue in high risk breast cancers. Our strategy contrasts with the CALGB 8541 trial since it investigated anthracycline-based regimens where half of patients had less than three positive nodes.
Despite the relatively small number of patients in the present analysis, our data strongly suggest an adverse result: high-dose alkylating chemotherapy (HDC) with Table 3 Multivariate analysis of erb B2 status combined with ER status
Parameter
Odds radio
Overall survival erb B2 negative 1 erb B2 positive 5.28 (1.74-16.03) P: 0.003 Event-free survival erb B2 negative 1 erb B2 positive 3.25 (1.12-9.45) P 0.03
Bone Marrow Transplantation hematopoietic stem cell support (HSC) failed to reverse the pejorative prognostic value of erb B2 overexpression in breast cancers (RR: 5.28 for overall survival). In the nine patients with erb B2 overexpression, 5-year overall survival is 33% and disease-free survival 27.7%, significantly shorter than in the general population and patients with low or no erb B2 expression. The benefit of higher doses of alkylating agents does not appear clearly in tumors with erb B2 overexpression. The prognostic value of erb B2 in breast cancers treated with high-dose chemotherapy and autologous stem cell transplantation remains poorly investigated. Similar results to those in this study had been suggested in 26 patients with more than 10 involved nodes treated with six cycles of standard chemotherapy followed by cyclophosphamide (2500 mg/m 2 on days Ϫ6, Ϫ4, Ϫ2) thiotepa (225 mg/m 2 days Ϫ6, Ϫ4, Ϫ2) and HSC rescue. 18 With a median follow-up of 2 years, four relapses occurred, all in erb B2-positive tumors. The four patients with erb B2-positive tumors relapsed, whereas the 21 patients who had low expression of erb B2 did not (P ϭ 0.00004, Fisher's test). A large retrospective trial has recently reported results consistent with ours. Adjuvant high-dose chemotherapy (cisplatin, thiotepa and cyclophosphamide) with hematopoietic stem cells was administrated to 154 high risk patients with more than 10 involved nodes (n ϭ 66), more than four involved nodes (n ϭ 56) and inflammatory breast cancers (n ϭ 24). Median follow-up was 42 months. Despite pronounced heterogeneity of inclusion criteria, disease-free survival and overall survival were significantly shorter when erb B2 was overexpressed (P ϭ 0.02 and 0.02, respectively). The authors completed their analysis using a score system based on the three variables predictive of relapse after transplantation, 19 nodal ratio, tumor size and ER/PR status. Scores у2.41 indicated high risk of relapse after HDCT. Combined application of the scoring system and Her 2/neu status established three groups of patients: high score regardless of Her 2 status, low score -Her 2-positive tumors and low score -Her 2-positive tumors with respective RFS rates 41.7%, 71% and 93.8% (P ϭ 0.0000006). Therefore, the addition of Her 2/neu overexpression to patient score has no impact for high score patients, suggesting that significant nodal involvement, large tumor size and lack of hormonal receptors determine a poor risk subgroup of patients for whom length of new biological factors such as erbB2 overexpression is low. In contrast, erbB2 overexpression might be a useful additional predictor factor for the low risk subset. The predictive value of erb B2 reported in the Bitran study 18 and in our analysis is consistent with the relatively small tumor size and the positive hormonal receptors resulting in low risk of relapse for our patients.
These findings would benefit from further study but do suggest an interesting further hypothesis. How can the results of this study be reconciled with those published by Muss? Recent data suggest that tumors with erb B2 overexpression overexpress topoisomerase II alpha (topo II ␣ resulting in a higher response rate to doxorubicine which is a topo II ␣ inhibitor. 20 The correlation between erb B2 overexpression and chemosensitivity to alkylating agents remains controversial.
How can the pejorative prognosis be reversed in patients in whom erb B2 is overexpressed? Herceptin, a humanized antibody that binds to the extracellular domain of erb B2 represents an exciting potential treatment in these patients after alkylating-based HDC and hematopoietic stem cell rescue. In vitro, synergistic interaction between monoclonal antibody specific against erb B2 and thiotepa supports the potential role of erb B2 overexpression among responses to alkylating agents 21 and the interest in herceptin after alkylating-based HDC. However, less than 20% of metastatic breast cancers with erb B2 overexpression respond to herceptin when used alone 22, 23 and an optimal strategy for its administration requires further investigation. Herceptin might be used after HDC in erb B2-positive tumors. However, risk of cardiac toxicity when combined with anthracycline delays this maintenance treatment and requires a specific study. Optimal duration is unknown; however, 6 to 12 months appears feasible and effective. We suggest that erb B2ϩ patients who have undergone HDC with PBSC support could receive herceptine weekly until progression, side effects or for 12 months.
Finally, despite the small number of patients, it was found that high-dose alkylating agents with hematopoietic stem cell support failed to reverse the pejorative prognosis value of erb B2 overexpression in terms of overall and disease-free survivals in patients with high risk breast cancer. Additional studies are required to confirm our observation in the light of the opposing data found with highdose anthracyclines. If confirmed, further strategies using monoclonal antibodies such as herceptin must be developed for use after high-dose alkylating agents and HSC rescue in order to overcome this negative prognostic factor.
